Epigenetic drug therapy based on bromodomain inhibition

Epigenomics

Volumn 6, Issue 5, 2014, Pages 473-476

  Bayarsaihan, Dashzeveg ^a   Shin, Dong Guk ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

BET family; bromodomain; epigenetic inhibitors; histone acetylation; small molecule therapies

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; 6 (4 CHLOROPHENYL) N ETHYL 8 METHOXY 1 METHYL 4H [1,2,4]TRIAZOLO[4,3 A][1,4]BENZODIAZEPINE 4 ACETAMIDE; 7 (3,5 DIMETHYL 4 ISOXAZOLYL) 1,3 DIHYDRO 8 METHOXY 1 [1 (2 PYRIDINYL)ETHYL] 2H IMIDAZO[4,5 C]QUINOLIN 2 ONE; APABETALONE; BROMODOMAIN INHIBITOR; UNCLASSIFIED DRUG; ZINC01411240; ZINC04818522; ZINC19632618; NUCLEAR PROTEIN;

DRUG MECHANISM; DRUG THERAPY; ENZYME INHIBITION; EPIGENETICS; HUMAN; HUMAN GENOME; MOLECULARLY TARGETED THERAPY; NONHUMAN; NOTE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; GENETIC EPIGENESIS; METABOLISM; PROTEIN DOMAIN;

DRUG DISCOVERY; EPIGENESIS, GENETIC; HUMANS; NUCLEAR PROTEINS; PROTEIN INTERACTION DOMAINS AND MOTIFS;

EID: 84913610674     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.14.45     Document Type: Note

References (39)

1. Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat. Rev. Drug Discov. 13(5), 337-356 (2014).
2. Gallenkamp D, Gelato KA, Haendler B et al. Bromodomains and their pharmacological inhibitors. Chem. Med. Chem. 9(3), 438-464 (2014).
3. Shi J, Vakoc CR. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol. Cell 54(5), 728-736 (2014).
4. Lovén J, Hoke HA, Lin CY et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153(2), 320-334 (2013).
5. Hnisz D, Abraham BJ, Lee TI et al. Super-enhancers in the control of cell identity and disease. Cell 155(4), 934-947 (2013).
6. Meng S, Zhang L, Tang Y et al. BET inhibitor JQ1 blocks infammation and bone destruction. J. Dent. Res. 93(7), 657-662 (2014).
7. Tang X, Peng R, Phillips JE et al. Assessment of Brd4 inhibition in idiopathic pulmonary fbrosis lung fbroblasts and in vivo models of lung fbrosis. Am. J. Pathol. 183(2), 470-479 (2013).
8. Lamoureux F, Baud'huin M, Rodriguez Calleja L et al. Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle. Nat. Commun. 5, 355 (2014).
9. Michaeloudes C, Mercado N, Clarke C et al. Bromodomain and extraterminal proteins suppress NF-E2-related factor 2-mediated antioxidant gene expression. J. Immunol. 192(10), 4913-4920 (2014).
10. Hussong M, Börno ST, Kerick M et al. The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response. Cell Death Dis. 5, e1195 (2014).
11. Ray S, Zhao Y, Jamaluddin M et al. Inducible STAT3 NH2 terminal mono-ubiquitination promotes BRD4 complex formation to regulate apoptosis. Cell Signal. 26(7), 1445-1455 (2014).
12. Liu S, Walker SR, Nelson EA et al. Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2. Mol. Cancer Ther. 13(5), 1194-1205 (2014).
13. Trabucco SE, Gerstein RM, Evens AM et al. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. Clin. Cancer Res. (2014) (In Press).
14. Stewart HJ, Horne GA, Bastow S et al. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1. Cancer Med. 2(6), 826-835 (2013).
15. Henssen A, Thor T, Odersky A et al. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Oncotarget 4(11), 2080-2095 (2013).
16. Da Costa D, Agathanggelou A, Perry T et al. BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia. Blood Cancer J. 3, e126 (2013).
17. Roderick JE, Tesell J, Shultz LD et al. c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood 123(7), 1040-1050 (2014).
18. Loosveld M, Castellano R, Gon S et al. Therapeutic targeting of c-Myc in T-Cell acute lymphoblastic leukemia, T-ALL. Oncotarget 5 (10), 3168-3172 (2014).
19. Fiskus W, Sharma S, Qi J et al. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol. Cancer Ther. 13(5), 1142-1154 (2014).
20. Tang Y, Gholamin S, Schubert S et al. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat. Med. 20(7), 732-740 (2014).
21. Gallagher SJ, Mijatov B, Gunatilake D et al. Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151. Pigment Cell Melanoma Res. (2014) (In Press).
22. Barrett E, Brothers S, Wahlestedt C et al. I-BET 151 selectively regulates IL-6 production. Biochim. Biophys. Acta 1842(9), 1549-1555 (2014).
23. Chaidos A, Caputo V, Gouvedenou K et al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood 123(5), 697-705 (2014).
24. Wyspiańska BS, Bannister AJ, Barbieri I et al. BET protein inhibition shows effcacy against JAK2V617F-driven neoplasms. Leukemia 28(1), 88-97 (2014).
25. Pastori C, Daniel M, Penas C et al. BET bromodomain proteins are required for glioblastoma cell proliferation. Epigenetics 9(4), 611-620 (2014).
26. Wyce A, Degenhardt Y, Bai Y et al. Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer. Oncotarget 4(12), 2419-2429 (2013).
27. Zhao Y, Yang CY, Wang S. The making of I-BET762, a BET bromodomain inhibitor now in clinical development. J. Med. Chem. 56(19), 7498-7500 (2013).
28. Picaud S, Wells C, Felletar I et al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc. Natl Acad. Sci. USA 110 (49), 19754-19759 (2013).
29. Jahagirdar R, Zhang H, Azhar S et al. A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE defcient mice. Atherosclerosis 236(1), 91-100 (2014).
30. Gacias M, Gerona-Navarro G, Plotnikov AN et al. Selective chemical modulation of gene transcription favors oligodendrocyte lineage progression. Chem. Biol. 21(7), 841-854 (2014).
31. Bhadury J, Nilsson LM, Veppil Muralidharan S et al. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proc. Natl Acad. Sci. USA 111(26), E2721-E2730 (2014).
32. Devaiah BN, Lewis BA, Cherman N et al. BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proc. Natl Acad. Sci. USA 109(18), 6927-6932 (2012).
33. Wang R, Li Q, Helfer CM et al. Bromodomain protein Brd4 associated with acetylated chromatin is important for maintenance of higher-order chromatin structure. J. Biol. Chem. 287, 10738-10752 (2012).
34. Martin MP, Olesen SH, Georg GI et al. Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. ACS Chem. Biol. 8(11), 2360-2365 (2013).
35. Ember SW, Zhu JY, Olesen SH et al. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors. ACS Chem. Biol. 9(5), 1160-1171 (2014).
36. Dittmann A, Werner T, Chung CW et al. The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains. ACS Chem. Biol. 9, 495-502 (2014).
37. Muvva C, Singam ER, Raman SS et al. Structure-based virtual screening of novel, high-affnity BRD4 inhibitors. Mol. Biosyst. 10(9), 2384-2397 (2014).
38. Liu R, Zhong Y, Li X et al. Role of transcription factor acetylation in diabetic kidney disease. Diabetes 63(7), 2440-2453 (2014).
39. Moros A, Rodríguez V, Saborit-Villarroya I et al. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma. Leukemia doi:10.1038/eu.2014.106 (2014) (Epub ahead of print).